Lorna Moore
Concepts (451)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Altitude | 85 | 2025 | 488 | 14.180 |
Why?
| | Uterine Artery | 17 | 2024 | 80 | 5.710 |
Why?
| | Fetal Growth Retardation | 34 | 2025 | 566 | 5.530 |
Why?
| | Hypoxia | 40 | 2025 | 1112 | 4.600 |
Why?
| | Pre-Eclampsia | 17 | 2024 | 190 | 4.570 |
Why?
| | Fetal Hypoxia | 12 | 2024 | 54 | 3.980 |
Why?
| | Pregnancy | 78 | 2025 | 6771 | 3.530 |
Why?
| | Uterus | 15 | 2020 | 214 | 3.200 |
Why?
| | Acclimatization | 20 | 2019 | 177 | 3.170 |
Why?
| | Placenta | 17 | 2025 | 750 | 2.870 |
Why?
| | AMP-Activated Protein Kinases | 8 | 2025 | 197 | 2.820 |
Why?
| | Altitude Sickness | 18 | 2022 | 153 | 2.610 |
Why?
| | Placental Circulation | 10 | 2025 | 71 | 2.360 |
Why?
| | Fetal Development | 9 | 2024 | 296 | 2.360 |
Why?
| | Birth Weight | 23 | 2024 | 516 | 2.160 |
Why?
| | Vasodilation | 10 | 2022 | 499 | 1.910 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2023 | 69 | 1.900 |
Why?
| | Arteries | 10 | 2022 | 269 | 1.900 |
Why?
| | Oxygen | 17 | 2023 | 938 | 1.850 |
Why?
| | Adaptation, Physiological | 12 | 2021 | 554 | 1.770 |
Why?
| | Bolivia | 20 | 2024 | 65 | 1.630 |
Why?
| | Biological Evolution | 6 | 2025 | 475 | 1.530 |
Why?
| | Vasoconstriction | 5 | 2015 | 202 | 1.400 |
Why?
| | Regional Blood Flow | 10 | 2024 | 481 | 1.240 |
Why?
| | Middle Cerebral Artery | 2 | 2024 | 53 | 1.080 |
Why?
| | Female | 102 | 2025 | 73365 | 1.070 |
Why?
| | Nitric Oxide Synthase | 4 | 2019 | 240 | 1.030 |
Why?
| | Myometrium | 2 | 2020 | 39 | 1.020 |
Why?
| | Selection, Genetic | 8 | 2019 | 274 | 1.010 |
Why?
| | Fertility | 2 | 2021 | 160 | 0.920 |
Why?
| | Endothelium, Vascular | 4 | 2019 | 927 | 0.900 |
Why?
| | Oxygen Consumption | 15 | 2012 | 706 | 0.890 |
Why?
| | HELLP Syndrome | 1 | 2023 | 6 | 0.840 |
Why?
| | Hemodynamics | 9 | 2024 | 1112 | 0.800 |
Why?
| | Humans | 107 | 2025 | 137621 | 0.750 |
Why?
| | Adult | 59 | 2024 | 37947 | 0.750 |
Why?
| | Vascular Resistance | 7 | 2024 | 375 | 0.750 |
Why?
| | Tibet | 14 | 2021 | 27 | 0.740 |
Why?
| | Pregnancy, Animal | 4 | 2006 | 52 | 0.710 |
Why?
| | Infant, Newborn | 23 | 2024 | 6084 | 0.710 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2019 | 446 | 0.710 |
Why?
| | Gestational Age | 11 | 2024 | 910 | 0.690 |
Why?
| | Hemoglobins | 8 | 2017 | 353 | 0.680 |
Why?
| | Pregnancy Outcome | 4 | 2019 | 416 | 0.650 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.650 |
Why?
| | Exercise | 8 | 2018 | 2063 | 0.650 |
Why?
| | Adrenergic alpha-Antagonists | 4 | 2003 | 36 | 0.620 |
Why?
| | Fetus | 6 | 2025 | 806 | 0.610 |
Why?
| | Polycythemia | 3 | 2017 | 21 | 0.610 |
Why?
| | Pregnancy Complications | 6 | 2017 | 527 | 0.600 |
Why?
| | Maternal-Fetal Exchange | 4 | 2021 | 165 | 0.590 |
Why?
| | Protein Kinases | 1 | 2020 | 319 | 0.570 |
Why?
| | Maternal Health Services | 1 | 2019 | 102 | 0.540 |
Why?
| | Catecholamines | 8 | 2003 | 98 | 0.510 |
Why?
| | Menstrual Cycle | 7 | 2003 | 133 | 0.480 |
Why?
| | Infant, Small for Gestational Age | 3 | 2011 | 92 | 0.480 |
Why?
| | Women's Health | 2 | 2011 | 372 | 0.470 |
Why?
| | Nitric Oxide | 4 | 2020 | 915 | 0.470 |
Why?
| | Pulmonary Circulation | 2 | 2021 | 429 | 0.440 |
Why?
| | Receptor, Endothelin A | 1 | 2014 | 65 | 0.440 |
Why?
| | Animals | 26 | 2025 | 36935 | 0.430 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 318 | 0.430 |
Why?
| | Aromatase | 1 | 2014 | 32 | 0.430 |
Why?
| | Genetics, Population | 6 | 2010 | 214 | 0.420 |
Why?
| | Endothelin-1 | 2 | 2020 | 182 | 0.400 |
Why?
| | Blood Pressure | 11 | 2020 | 1789 | 0.400 |
Why?
| | Polymorphism, Single Nucleotide | 10 | 2019 | 2189 | 0.400 |
Why?
| | Ultrasonography, Doppler | 3 | 2020 | 125 | 0.390 |
Why?
| | Indians, South American | 6 | 2015 | 25 | 0.390 |
Why?
| | PPAR gamma | 3 | 2020 | 182 | 0.390 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 77 | 0.380 |
Why?
| | Respiratory Mechanics | 4 | 2007 | 67 | 0.380 |
Why?
| | Phenylephrine | 6 | 2020 | 75 | 0.380 |
Why?
| | Estrogens | 2 | 2014 | 366 | 0.380 |
Why?
| | Angiotensin II | 2 | 2011 | 99 | 0.370 |
Why?
| | Sleep Apnea Syndromes | 1 | 2013 | 88 | 0.370 |
Why?
| | Infant, Low Birth Weight | 2 | 2011 | 141 | 0.370 |
Why?
| | Guinea Pigs | 8 | 2006 | 158 | 0.370 |
Why?
| | Young Adult | 12 | 2024 | 13226 | 0.360 |
Why?
| | Gene Frequency | 5 | 2014 | 521 | 0.360 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2011 | 9 | 0.360 |
Why?
| | Enzymes | 1 | 2011 | 67 | 0.360 |
Why?
| | Health Services Accessibility | 1 | 2019 | 988 | 0.350 |
Why?
| | Travel | 1 | 2012 | 130 | 0.350 |
Why?
| | Genome, Human | 4 | 2012 | 423 | 0.350 |
Why?
| | Homeostasis | 2 | 2014 | 621 | 0.340 |
Why?
| | Prazosin | 5 | 2003 | 23 | 0.340 |
Why?
| | Angiostatic Proteins | 1 | 2010 | 5 | 0.340 |
Why?
| | Angiogenic Proteins | 1 | 2010 | 16 | 0.340 |
Why?
| | South America | 5 | 2017 | 60 | 0.330 |
Why?
| | Infant Mortality | 2 | 2021 | 116 | 0.330 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 71 | 0.320 |
Why?
| | Interleukin-1beta | 1 | 2010 | 372 | 0.290 |
Why?
| | Ultrasonography, Prenatal | 3 | 2024 | 286 | 0.290 |
Why?
| | 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 2 | 2011 | 4 | 0.280 |
Why?
| | Mountaineering | 2 | 2005 | 40 | 0.280 |
Why?
| | Antioxidants | 1 | 2011 | 585 | 0.280 |
Why?
| | Heart Rate | 7 | 2015 | 824 | 0.270 |
Why?
| | Case-Control Studies | 6 | 2024 | 3567 | 0.270 |
Why?
| | Chronic Disease | 9 | 2013 | 1794 | 0.260 |
Why?
| | Europe | 4 | 2009 | 414 | 0.260 |
Why?
| | Blood Flow Velocity | 4 | 2011 | 420 | 0.250 |
Why?
| | Oxidative Stress | 1 | 2013 | 1317 | 0.250 |
Why?
| | Vasoconstrictor Agents | 3 | 2020 | 139 | 0.250 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2005 | 42 | 0.240 |
Why?
| | Acetylcholine | 2 | 2020 | 185 | 0.240 |
Why?
| | Autonomic Nervous System | 1 | 2005 | 76 | 0.240 |
Why?
| | Research | 2 | 2005 | 451 | 0.230 |
Why?
| | Fetal Death | 2 | 2003 | 55 | 0.230 |
Why?
| | Placental Insufficiency | 2 | 2023 | 116 | 0.220 |
Why?
| | Epinephrine | 3 | 2001 | 141 | 0.220 |
Why?
| | Cytokines | 2 | 2010 | 2085 | 0.220 |
Why?
| | Umbilical Arteries | 1 | 2024 | 55 | 0.220 |
Why?
| | Embryonic and Fetal Development | 2 | 2003 | 97 | 0.220 |
Why?
| | Infant | 6 | 2021 | 9482 | 0.210 |
Why?
| | Mammals | 2 | 2022 | 283 | 0.210 |
Why?
| | Norepinephrine | 3 | 2001 | 204 | 0.210 |
Why?
| | Models, Genetic | 2 | 2007 | 600 | 0.210 |
Why?
| | Chi-Square Distribution | 2 | 2018 | 529 | 0.210 |
Why?
| | Peru | 2 | 2021 | 58 | 0.210 |
Why?
| | Parity | 2 | 2018 | 126 | 0.210 |
Why?
| | Mice | 8 | 2021 | 17789 | 0.210 |
Why?
| | Mining | 1 | 2003 | 22 | 0.200 |
Why?
| | Interleukin-6 | 2 | 2010 | 778 | 0.200 |
Why?
| | Amino Acids | 3 | 2023 | 497 | 0.200 |
Why?
| | Speech Production Measurement | 1 | 2002 | 12 | 0.200 |
Why?
| | Silver | 1 | 2003 | 38 | 0.190 |
Why?
| | Speech Disorders | 1 | 2002 | 31 | 0.190 |
Why?
| | In Vitro Techniques | 4 | 2011 | 1091 | 0.190 |
Why?
| | Receptors, Adrenergic, alpha-1 | 2 | 2001 | 45 | 0.190 |
Why?
| | Geography | 3 | 2011 | 200 | 0.190 |
Why?
| | Cerebrovascular Circulation | 1 | 2024 | 250 | 0.190 |
Why?
| | Regression Analysis | 3 | 2018 | 1024 | 0.190 |
Why?
| | Myoglobin | 1 | 2002 | 13 | 0.190 |
Why?
| | Carbohydrate Metabolism | 2 | 2000 | 59 | 0.190 |
Why?
| | Progesterone | 5 | 2003 | 254 | 0.190 |
Why?
| | Vasodilator Agents | 2 | 2020 | 331 | 0.180 |
Why?
| | Potassium Channels | 2 | 2022 | 151 | 0.180 |
Why?
| | Erythropoiesis | 1 | 2001 | 55 | 0.180 |
Why?
| | Adrenergic alpha-Agonists | 4 | 2003 | 28 | 0.180 |
Why?
| | Trophoblasts | 2 | 2019 | 199 | 0.180 |
Why?
| | Motor Skills | 1 | 2002 | 97 | 0.180 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 840 | 0.180 |
Why?
| | Developing Countries | 1 | 2023 | 308 | 0.180 |
Why?
| | Gene Expression Regulation | 4 | 2021 | 2607 | 0.170 |
Why?
| | Reproduction | 1 | 2003 | 204 | 0.170 |
Why?
| | Luteal Phase | 5 | 2001 | 45 | 0.170 |
Why?
| | Signal Transduction | 3 | 2024 | 5084 | 0.170 |
Why?
| | Pyrones | 1 | 2020 | 8 | 0.170 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2020 | 12 | 0.170 |
Why?
| | Male | 26 | 2019 | 67800 | 0.170 |
Why?
| | Glycolysis | 2 | 2021 | 321 | 0.170 |
Why?
| | Ribonucleotides | 1 | 2020 | 26 | 0.170 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2000 | 31 | 0.170 |
Why?
| | Muscle Relaxation | 1 | 2000 | 19 | 0.170 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 125 | 0.160 |
Why?
| | Genotype | 4 | 2014 | 1918 | 0.160 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1910 | 0.160 |
Why?
| | Biphenyl Compounds | 1 | 2020 | 63 | 0.160 |
Why?
| | Reproductive Health | 1 | 2021 | 90 | 0.160 |
Why?
| | Genetic Markers | 3 | 2012 | 344 | 0.160 |
Why?
| | Thiophenes | 1 | 2020 | 117 | 0.160 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 179 | 0.160 |
Why?
| | Risk Factors | 5 | 2019 | 10401 | 0.160 |
Why?
| | Arterial Pressure | 2 | 2017 | 128 | 0.160 |
Why?
| | Respiratory Function Tests | 3 | 2013 | 601 | 0.160 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 2 | 2017 | 21 | 0.150 |
Why?
| | Erythropoietin | 2 | 2017 | 95 | 0.150 |
Why?
| | Blood Volume | 4 | 2007 | 61 | 0.150 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5764 | 0.150 |
Why?
| | Biological Transport | 3 | 2019 | 419 | 0.150 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2001 | 323 | 0.150 |
Why?
| | Blood Gas Analysis | 3 | 2007 | 74 | 0.150 |
Why?
| | Follicular Phase | 5 | 2001 | 39 | 0.150 |
Why?
| | Glyburide | 1 | 1998 | 32 | 0.150 |
Why?
| | Adipose Tissue, White | 1 | 2018 | 41 | 0.150 |
Why?
| | Health Promotion | 1 | 2005 | 742 | 0.150 |
Why?
| | Maternal Age | 1 | 2018 | 129 | 0.140 |
Why?
| | Estradiol | 5 | 2003 | 521 | 0.140 |
Why?
| | Sudden Infant Death | 1 | 1998 | 29 | 0.140 |
Why?
| | Analysis of Variance | 3 | 2011 | 1314 | 0.140 |
Why?
| | Body Weights and Measures | 2 | 2015 | 36 | 0.140 |
Why?
| | Intraocular Pressure | 1 | 2000 | 307 | 0.140 |
Why?
| | Delivery, Obstetric | 2 | 2011 | 144 | 0.140 |
Why?
| | Respiration | 3 | 2005 | 199 | 0.140 |
Why?
| | DNA | 2 | 2006 | 1459 | 0.140 |
Why?
| | Ethiopia | 1 | 2017 | 41 | 0.140 |
Why?
| | Cohort Studies | 4 | 2020 | 5725 | 0.140 |
Why?
| | Glucose | 2 | 2023 | 1020 | 0.140 |
Why?
| | Physical Endurance | 2 | 2001 | 275 | 0.130 |
Why?
| | Models, Biological | 4 | 2015 | 1782 | 0.130 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 24 | 0.130 |
Why?
| | Vascular Diseases | 2 | 2017 | 243 | 0.130 |
Why?
| | Ovariectomy | 1 | 1997 | 152 | 0.130 |
Why?
| | Receptors, Erythropoietin | 1 | 2017 | 20 | 0.130 |
Why?
| | Linear Models | 2 | 2014 | 849 | 0.130 |
Why?
| | Pulmonary Gas Exchange | 2 | 2015 | 121 | 0.130 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5474 | 0.130 |
Why?
| | Time Factors | 8 | 2011 | 6831 | 0.120 |
Why?
| | Cardiovascular System | 1 | 2017 | 137 | 0.120 |
Why?
| | Pregnancy Complications, Cardiovascular | 3 | 2007 | 77 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2023 | 545 | 0.120 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 243 | 0.110 |
Why?
| | Electrocardiography | 1 | 1998 | 629 | 0.110 |
Why?
| | Adolescent | 5 | 2019 | 21560 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 518 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1509 | 0.110 |
Why?
| | Polymorphism, Genetic | 2 | 2012 | 659 | 0.110 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2015 | 204 | 0.110 |
Why?
| | Receptor, Endothelin B | 1 | 2014 | 51 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2799 | 0.110 |
Why?
| | Double-Blind Method | 4 | 2003 | 1997 | 0.110 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 51 | 0.110 |
Why?
| | Severity of Illness Index | 1 | 2002 | 2841 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2022 | 15620 | 0.110 |
Why?
| | Body Height | 2 | 2013 | 199 | 0.110 |
Why?
| | Sex Characteristics | 5 | 2001 | 763 | 0.100 |
Why?
| | Phenotype | 2 | 2023 | 3200 | 0.100 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2021 | 605 | 0.100 |
Why?
| | Body Weight | 3 | 2007 | 985 | 0.100 |
Why?
| | Atmosphere Exposure Chambers | 2 | 2002 | 7 | 0.100 |
Why?
| | Gonadal Steroid Hormones | 1 | 2014 | 140 | 0.100 |
Why?
| | Brain | 1 | 2024 | 2676 | 0.100 |
Why?
| | Pulmonary Artery | 2 | 2015 | 1088 | 0.100 |
Why?
| | Optic Atrophy, Hereditary, Leber | 1 | 2012 | 5 | 0.100 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2012 | 48 | 0.100 |
Why?
| | Pregnancy Trimesters | 1 | 2012 | 19 | 0.100 |
Why?
| | Genetic Association Studies | 1 | 2014 | 377 | 0.100 |
Why?
| | Indomethacin | 1 | 2012 | 81 | 0.100 |
Why?
| | NADH Dehydrogenase | 1 | 2012 | 19 | 0.090 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2012 | 79 | 0.090 |
Why?
| | Hypertension | 3 | 2015 | 1299 | 0.090 |
Why?
| | Lactic Acid | 3 | 2023 | 305 | 0.090 |
Why?
| | Reference Values | 4 | 2003 | 815 | 0.090 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 305 | 0.090 |
Why?
| | Polysomnography | 1 | 2013 | 185 | 0.090 |
Why?
| | Age Factors | 2 | 2011 | 3299 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2734 | 0.090 |
Why?
| | Apgar Score | 1 | 2011 | 17 | 0.090 |
Why?
| | Colorado | 5 | 2019 | 4576 | 0.090 |
Why?
| | Atmospheric Pressure | 2 | 2001 | 23 | 0.090 |
Why?
| | Potassium Chloride | 1 | 2011 | 38 | 0.090 |
Why?
| | Population Dynamics | 1 | 2012 | 151 | 0.090 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 411 | 0.090 |
Why?
| | Nitroarginine | 2 | 2002 | 56 | 0.090 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2011 | 32 | 0.090 |
Why?
| | Live Birth | 1 | 2011 | 66 | 0.090 |
Why?
| | Iliac Artery | 1 | 2011 | 55 | 0.090 |
Why?
| | DNA, Mitochondrial | 1 | 2012 | 200 | 0.090 |
Why?
| | Middle Aged | 5 | 2019 | 33465 | 0.080 |
Why?
| | Stillbirth | 1 | 2011 | 72 | 0.080 |
Why?
| | DNA Methylation | 1 | 2015 | 643 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2011 | 329 | 0.080 |
Why?
| | Child Development | 1 | 2015 | 475 | 0.080 |
Why?
| | Pregnancy Proteins | 1 | 2010 | 36 | 0.080 |
Why?
| | Sympathetic Nervous System | 2 | 2003 | 182 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4287 | 0.080 |
Why?
| | Ultrasonography | 1 | 2014 | 761 | 0.080 |
Why?
| | Alleles | 3 | 2012 | 892 | 0.080 |
Why?
| | Haplotypes | 3 | 2017 | 494 | 0.080 |
Why?
| | Anthropology, Physical | 1 | 2009 | 28 | 0.080 |
Why?
| | Interleukin-4 | 1 | 2010 | 216 | 0.080 |
Why?
| | Mesenteric Arteries | 2 | 2000 | 16 | 0.080 |
Why?
| | Renal Circulation | 3 | 1998 | 65 | 0.080 |
Why?
| | Sheep | 2 | 2023 | 856 | 0.080 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 253 | 0.080 |
Why?
| | Genomics | 2 | 2023 | 795 | 0.080 |
Why?
| | Databases, Genetic | 1 | 2010 | 237 | 0.080 |
Why?
| | Pedigree | 1 | 2010 | 514 | 0.080 |
Why?
| | Lung Diseases | 1 | 2015 | 767 | 0.080 |
Why?
| | Up-Regulation | 1 | 2011 | 840 | 0.070 |
Why?
| | Interleukin-10 | 1 | 2010 | 302 | 0.070 |
Why?
| | Ovary | 2 | 2018 | 221 | 0.070 |
Why?
| | Basal Metabolism | 3 | 2003 | 61 | 0.070 |
Why?
| | Exercise Test | 3 | 2001 | 632 | 0.070 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1457 | 0.070 |
Why?
| | Lung | 1 | 2021 | 4060 | 0.070 |
Why?
| | Heart Rate, Fetal | 1 | 2007 | 21 | 0.070 |
Why?
| | Head | 1 | 2008 | 103 | 0.070 |
Why?
| | Premature Birth | 1 | 2011 | 333 | 0.070 |
Why?
| | Biometry | 1 | 2007 | 70 | 0.070 |
Why?
| | Prospective Studies | 3 | 2022 | 7599 | 0.070 |
Why?
| | Aorta, Thoracic | 2 | 2000 | 267 | 0.070 |
Why?
| | Urban Health | 1 | 2007 | 92 | 0.070 |
Why?
| | Health Status | 1 | 2011 | 793 | 0.060 |
Why?
| | Indians, North American | 2 | 2009 | 643 | 0.060 |
Why?
| | Femur | 1 | 2008 | 254 | 0.060 |
Why?
| | Phylogeny | 2 | 2010 | 904 | 0.060 |
Why?
| | Respiratory Distress Syndrome, Newborn | 1 | 2007 | 106 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2007 | 522 | 0.060 |
Why?
| | Serum | 1 | 2006 | 59 | 0.060 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2006 | 72 | 0.060 |
Why?
| | Hyperplasia | 1 | 2006 | 175 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1243 | 0.060 |
Why?
| | Cell Count | 1 | 2006 | 324 | 0.060 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 2 | 2001 | 17 | 0.060 |
Why?
| | Longitudinal Studies | 3 | 2019 | 2861 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2012 | 2427 | 0.060 |
Why?
| | History, 21st Century | 1 | 2005 | 213 | 0.060 |
Why?
| | Mental Health | 1 | 2011 | 728 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2011 | 5797 | 0.060 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 192 | 0.060 |
Why?
| | History, 20th Century | 1 | 2005 | 325 | 0.060 |
Why?
| | Plasma Volume | 1 | 2003 | 19 | 0.050 |
Why?
| | Child | 4 | 2015 | 21985 | 0.050 |
Why?
| | Cardiac Output | 3 | 1998 | 172 | 0.050 |
Why?
| | Pyruvates | 1 | 2023 | 24 | 0.050 |
Why?
| | Gene Expression Profiling | 1 | 2010 | 1768 | 0.050 |
Why?
| | Embryo Implantation | 1 | 2003 | 30 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 278 | 0.050 |
Why?
| | History, 17th Century | 1 | 2003 | 16 | 0.050 |
Why?
| | Acute Disease | 2 | 2005 | 1006 | 0.050 |
Why?
| | Primary Prevention | 1 | 2005 | 196 | 0.050 |
Why?
| | Meclofenamic Acid | 1 | 2002 | 10 | 0.050 |
Why?
| | Lower Extremity | 1 | 2007 | 434 | 0.050 |
Why?
| | Biomechanical Phenomena | 1 | 2006 | 811 | 0.050 |
Why?
| | Ion Channels | 1 | 2023 | 133 | 0.050 |
Why?
| | Sound Spectrography | 1 | 2002 | 18 | 0.050 |
Why?
| | Glutamine | 1 | 2023 | 103 | 0.050 |
Why?
| | Speech Acoustics | 1 | 2002 | 12 | 0.050 |
Why?
| | Serine | 1 | 2023 | 141 | 0.050 |
Why?
| | Ischemia | 1 | 2006 | 409 | 0.050 |
Why?
| | Locomotion | 1 | 2003 | 106 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 79 | 0.050 |
Why?
| | Glycine | 1 | 2023 | 176 | 0.050 |
Why?
| | Muscle Fatigue | 2 | 2001 | 102 | 0.050 |
Why?
| | Cesarean Section | 1 | 2023 | 184 | 0.050 |
Why?
| | Partial Pressure | 1 | 2001 | 30 | 0.050 |
Why?
| | Anaerobic Threshold | 1 | 2001 | 28 | 0.050 |
Why?
| | Species Specificity | 1 | 2003 | 585 | 0.050 |
Why?
| | Blood Glucose | 3 | 2001 | 2191 | 0.050 |
Why?
| | Health Education | 1 | 2005 | 341 | 0.050 |
Why?
| | Plethysmography | 1 | 2001 | 106 | 0.050 |
Why?
| | C-Peptide | 2 | 2001 | 163 | 0.050 |
Why?
| | Veins | 1 | 2001 | 65 | 0.040 |
Why?
| | Pyruvic Acid | 1 | 2021 | 53 | 0.040 |
Why?
| | Forearm | 1 | 2001 | 119 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2003 | 347 | 0.040 |
Why?
| | Ventricular Pressure | 1 | 2021 | 48 | 0.040 |
Why?
| | Insulin | 3 | 2001 | 2411 | 0.040 |
Why?
| | Hyperbaric Oxygenation | 1 | 2021 | 39 | 0.040 |
Why?
| | Risk Assessment | 1 | 2010 | 3458 | 0.040 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.040 |
Why?
| | Posture | 1 | 2001 | 185 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 2002 | 484 | 0.040 |
Why?
| | Exons | 1 | 2002 | 354 | 0.040 |
Why?
| | Arginine | 1 | 2002 | 271 | 0.040 |
Why?
| | Genetic Variation | 1 | 2006 | 991 | 0.040 |
Why?
| | Asia | 1 | 2000 | 71 | 0.040 |
Why?
| | Tonometry, Ocular | 1 | 2000 | 97 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2001 | 1724 | 0.040 |
Why?
| | Bromodeoxyuridine | 1 | 2000 | 79 | 0.040 |
Why?
| | Muscle Contraction | 2 | 2001 | 424 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 491 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2002 | 563 | 0.040 |
Why?
| | Paleontology | 1 | 2000 | 21 | 0.040 |
Why?
| | Fetal Weight | 1 | 2000 | 56 | 0.040 |
Why?
| | Linguistics | 1 | 2000 | 27 | 0.040 |
Why?
| | Endothelium | 1 | 2000 | 123 | 0.040 |
Why?
| | Archaeology | 1 | 2000 | 39 | 0.040 |
Why?
| | Geographic Mapping | 1 | 2019 | 24 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2001 | 267 | 0.040 |
Why?
| | North America | 1 | 2000 | 313 | 0.040 |
Why?
| | Organ Size | 1 | 2000 | 477 | 0.040 |
Why?
| | Thiazolidinediones | 1 | 2020 | 137 | 0.040 |
Why?
| | Litter Size | 1 | 1998 | 17 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1998 | 37 | 0.040 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 285 | 0.040 |
Why?
| | Cell Division | 1 | 2000 | 794 | 0.040 |
Why?
| | Gene Expression | 1 | 2023 | 1503 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2006 | 4193 | 0.040 |
Why?
| | Carotid Sinus | 1 | 1997 | 2 | 0.040 |
Why?
| | Hormones | 1 | 1998 | 143 | 0.040 |
Why?
| | Adrenal Glands | 1 | 1998 | 78 | 0.040 |
Why?
| | Glucagon | 1 | 2018 | 109 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 429 | 0.030 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 1998 | 145 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2002 | 561 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 232 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2002 | 2057 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2002 | 1940 | 0.030 |
Why?
| | Chemoreceptor Cells | 1 | 1997 | 51 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 1998 | 413 | 0.030 |
Why?
| | Genome-Wide Association Study | 2 | 2017 | 1431 | 0.030 |
Why?
| | Cats | 1 | 1997 | 210 | 0.030 |
Why?
| | Glomerular Filtration Rate | 2 | 1998 | 746 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 366 | 0.030 |
Why?
| | China | 1 | 1997 | 215 | 0.030 |
Why?
| | Ferritins | 1 | 2017 | 64 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 616 | 0.030 |
Why?
| | Energy Intake | 1 | 2000 | 485 | 0.030 |
Why?
| | Child, Preschool | 2 | 2015 | 11106 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1760 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2020 | 1730 | 0.030 |
Why?
| | California | 1 | 2017 | 431 | 0.030 |
Why?
| | Renin-Angiotensin System | 2 | 2010 | 85 | 0.030 |
Why?
| | Anesthesia | 1 | 1997 | 188 | 0.030 |
Why?
| | Pulmonary Veins | 1 | 2015 | 99 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 853 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2000 | 922 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2015 | 560 | 0.020 |
Why?
| | Aged | 2 | 2017 | 23924 | 0.020 |
Why?
| | Latin America | 1 | 2012 | 93 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2012 | 307 | 0.020 |
Why?
| | Globins | 1 | 2010 | 22 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2010 | 22 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 660 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 1285 | 0.020 |
Why?
| | Thumb | 2 | 2001 | 25 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2010 | 181 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2012 | 810 | 0.020 |
Why?
| | Hydrocortisone | 2 | 2002 | 322 | 0.020 |
Why?
| | Cyclic GMP | 2 | 1998 | 93 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 4009 | 0.020 |
Why?
| | Indians, Central American | 1 | 2007 | 6 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2012 | 2900 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5122 | 0.020 |
Why?
| | Aging | 1 | 1998 | 1865 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 44 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2007 | 297 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7593 | 0.010 |
Why?
| | Biomarkers | 1 | 2017 | 4155 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2007 | 765 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 3407 | 0.010 |
Why?
| | Heart Failure | 1 | 2017 | 2237 | 0.010 |
Why?
| | International Cooperation | 1 | 2005 | 198 | 0.010 |
Why?
| | Genetic Testing | 1 | 2007 | 462 | 0.010 |
Why?
| | Tilt-Table Test | 1 | 2001 | 8 | 0.010 |
Why?
| | Placebos | 1 | 2001 | 199 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2001 | 155 | 0.010 |
Why?
| | Societies, Medical | 1 | 2005 | 819 | 0.010 |
Why?
| | Transducers, Pressure | 1 | 1999 | 12 | 0.010 |
Why?
| | Water-Electrolyte Balance | 1 | 2000 | 34 | 0.010 |
Why?
| | Fasting | 1 | 2001 | 281 | 0.010 |
Why?
| | Electric Stimulation | 1 | 1999 | 264 | 0.010 |
Why?
| | Nitrogen | 1 | 2000 | 168 | 0.010 |
Why?
| | Electrolytes | 1 | 1998 | 58 | 0.010 |
Why?
| | Pregnancy Trimester, First | 1 | 1998 | 140 | 0.010 |
Why?
| | Renin | 1 | 1997 | 35 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1997 | 57 | 0.010 |
Why?
| | Aldosterone | 1 | 1997 | 45 | 0.010 |
Why?
| | Bicarbonates | 1 | 1997 | 44 | 0.010 |
Why?
| | Nitrites | 1 | 1997 | 84 | 0.010 |
Why?
| | Nitrates | 1 | 1997 | 92 | 0.010 |
Why?
| | Chlorides | 1 | 1997 | 136 | 0.010 |
Why?
| | Cyclic AMP | 1 | 1997 | 234 | 0.010 |
Why?
| | Sodium | 1 | 1997 | 217 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2000 | 1062 | 0.010 |
Why?
| | Body Composition | 1 | 2000 | 684 | 0.010 |
Why?
| | Poverty | 1 | 1999 | 521 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2001 | 1211 | 0.010 |
Why?
|
|
Moore's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|